Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness. The AK-OTOF therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback